Traws Pharma, Inc.
TRAW
$1.86
$0.2012.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 227.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 227.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| SG&A Expenses | 11.69M | 12.29M | 10.90M | 10.10M | 10.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.13M | 25.14M | 24.32M | 20.87M | 19.60M |
| Operating Income | -24.90M | -24.91M | -24.09M | -20.65M | -19.37M |
| Income Before Tax | -140.05M | -166.52M | -140.79M | -137.05M | -18.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.05 | -166.52 | -140.79 | -137.05 | -18.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.05M | -166.52M | -140.79M | -137.05M | -18.16M |
| EBIT | -24.90M | -24.91M | -24.09M | -20.65M | -19.37M |
| EBITDA | -24.89M | -24.90M | -24.08M | -20.63M | -19.36M |
| EPS Basic | -101.67 | -109.76 | -141.34 | -138.17 | -21.60 |
| Normalized Basic EPS | -13.16 | -18.79 | -15.83 | -13.84 | -13.50 |
| EPS Diluted | -101.75 | -109.76 | -141.34 | -138.17 | -21.60 |
| Normalized Diluted EPS | -13.23 | -18.79 | -15.83 | -13.84 | -13.50 |
| Average Basic Shares Outstanding | 12.02M | 5.90M | 3.66M | 3.53M | 3.36M |
| Average Diluted Shares Outstanding | 12.27M | 5.90M | 3.66M | 3.53M | 3.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |